{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=15",
    "query": {
      "condition": "Carcinoma, Non Small Cell Lung",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 3680,
    "total_pages": 368,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Non+Small+Cell+Lung&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:15:09.245Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05802186",
      "title": "Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Lung Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Metastatic Malignant Neoplasm in the Lung",
        "Stage I Lung Cancer AJCC v8",
        "Stage II Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Radiology, Treatment Planning",
          "type": "OTHER"
        },
        {
          "name": "Stereotactic Body Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "X-Ray Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-11-20",
      "completion_date": "2031-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05802186"
    },
    {
      "nct_id": "NCT01457469",
      "title": "Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Limited Stage Small Cell Lung Cancer",
        "Recurrent Small Cell Lung Cancer",
        "Stage IA Non-small Cell Lung Cancer",
        "Stage IB Non-small Cell Lung Cancer",
        "Stage IIA Non-small Cell Lung Cancer",
        "Stage IIB Non-small Cell Lung Cancer",
        "Stage IIIA Non-small Cell Lung Cancer",
        "Stage IIIB Non-small Cell Lung Cancer",
        "Tobacco Use Disorder"
      ],
      "interventions": [
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "counseling intervention",
          "type": "OTHER"
        },
        {
          "name": "internet-based intervention",
          "type": "OTHER"
        },
        {
          "name": "telephone-based intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "nicotine replacement therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE",
        "BEHAVIORAL",
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2011-01",
      "completion_date": "2012-05",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01457469"
    },
    {
      "nct_id": "NCT03663166",
      "title": "Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Thoracic Radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "Platinum Based Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2018-11-20",
      "completion_date": "2021-10-22",
      "has_results": true,
      "last_update_posted_date": "2023-02-15",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 3,
      "location_summary": "Tampa, Florida • Chapel Hill, North Carolina • Durham, North Carolina",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03663166"
    },
    {
      "nct_id": "NCT02289456",
      "title": "Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2015-04-28",
      "completion_date": "2017-02-22",
      "has_results": true,
      "last_update_posted_date": "2018-12-07",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 8,
      "location_summary": "Boynton Beach, Florida • New Orleans, Louisiana • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02289456"
    },
    {
      "nct_id": "NCT07909031",
      "title": "CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)",
        "Gastric/GEJ",
        "Biliary Tract Cancer (BTC)",
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Ovarian Cancer",
        "Endometrial Cancer",
        "Cervical Cancer Metastatic",
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "CR-002",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Crescent Biopharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 219,
      "start_date": "2026-10-21",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-11-02",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 3,
      "location_summary": "Austin, Texas • Dallas, Texas • Fairfax, Virginia",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07909031"
    },
    {
      "nct_id": "NCT02588261",
      "title": "A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "naquotinib mesilate",
          "type": "DRUG"
        },
        {
          "name": "Erlotinib",
          "type": "DRUG"
        },
        {
          "name": "Gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2016-02-11",
      "completion_date": "2017-12-21",
      "has_results": true,
      "last_update_posted_date": "2024-12-10",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 25,
      "location_summary": "Beverly Hills, California • Fountain Valley, California • La Jolla, California + 21 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02588261"
    },
    {
      "nct_id": "NCT01814553",
      "title": "ADAM-Afatinib Diarrhea Assessment and Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "afatinib",
          "type": "DRUG"
        },
        {
          "name": "loperamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01814553"
    },
    {
      "nct_id": "NCT04332653",
      "title": "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Any Advanced Solid Tumors",
        "Triple Negative Breast Cancer",
        "Non Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Microsatellite Stable Colorectal Cancer",
        "Pancreatic Cancer",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "NT-I7",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab (KEYTRUDA®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeoImmuneTech",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 215,
      "start_date": "2020-06-10",
      "completion_date": "2025-01-13",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 8,
      "location_summary": "Tampa, Florida • Detroit, Michigan • St Louis, Missouri + 5 more",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04332653"
    },
    {
      "nct_id": "NCT02664181",
      "title": "Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With NSCLC: PRECISE Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "oral decitabine",
          "type": "DRUG"
        },
        {
          "name": "Tetrahydrouridine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2017-06-06",
      "completion_date": "2024-05-19",
      "has_results": true,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Cleveland, Ohio",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02664181"
    },
    {
      "nct_id": "NCT01454934",
      "title": "A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Eribulin",
          "type": "DRUG"
        },
        {
          "name": "TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 540,
      "start_date": "2011-12-09",
      "completion_date": "2016-05-02",
      "has_results": true,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-11-19T16:15:09.245Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Pleasant Hill, California • San Diego, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pleasant Hill",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01454934"
    }
  ]
}